Characterization of the Role of USP25 in EGFR Endocytosis

Total Page:16

File Type:pdf, Size:1020Kb

Characterization of the Role of USP25 in EGFR Endocytosis PhD degree in Molecular Medicine (curriculum in Molecular Oncology) European School of Molecular Medicine (SEMM), University of Milan and University of Naples “Federico II” Settore disciplinare: Bio/10 Characterization of the role of USP25 in EGFR endocytosis Nadine Caroline Woessner IFOM, Milan Matricola n. R08892 Supervisor: Dr. Simona Polo IFOM, Milan Anno accademico 2013-2014 TABLE OF CONTENTS LIST OF ABBREVIATIONS................................................................................................ 8 FIGURE AND TABLE INDEX .......................................................................................... 11 ABSTRACT ........................................................................................................................ 13 INTRODUCTION ............................................................................................................... 15 1 Endocytosis .................................................................................................................. 15 1.1 Endocytic entry routes .......................................................................................... 15 1.1.1 Clathrin-mediated endocytosis (CME) .......................................................... 16 1.1.2 Non-clathrin endocytosis (NCE) ................................................................... 16 1.2 Endocytic sorting .................................................................................................. 19 1.3 Transferrin as a model substrate for CME ............................................................ 20 1.4 Endocytosis and signalling.................................................................................... 21 1.4.1 Endocytosis regulates signalling.................................................................... 21 1.4.2 Signalling regulates endocytosis.................................................................... 23 1.4.3 Signalling endosomes .................................................................................... 25 2 The ubiquitin system .................................................................................................... 26 2.1 Ubiquitin in endocytosis ....................................................................................... 29 2.1.1 Ubiquitination of cargoes .............................................................................. 30 2.1.2 Ubiquitin and endocytic adaptors .................................................................. 31 2.1.3 Ubiquitin in endosomal sorting ..................................................................... 33 2.2 Deubiquitinating enzymes (DUBs) in endocytosis ............................................... 35 2.2.1 Mechanism of catalysis .................................................................................. 36 2 2.2.2 DUB families .................................................................................................37 2.2.3 DUB activity in early steps of endocytosis ....................................................39 2.2.4 DUB activity in later steps of endocytosis .....................................................40 2.2.5 DUB activity in the secretory pathway ..........................................................43 3 The EGFR system ........................................................................................................44 3.1 Ligand-induced EGFR signal transduction ...........................................................45 3.2 EGFR endocytosis and trafficking ........................................................................46 3.3 Role of ubiquitin in EGFR endocytosis ................................................................47 3.4 Role of DUBs in EGFR endocytosis .....................................................................51 4 USP25 ..........................................................................................................................52 5 Cullin 3 .........................................................................................................................55 5.1 Structure and regulation of Cullins........................................................................55 5.2 Cullin 3 in endocytosis ..........................................................................................56 MATERIAL AND METHODS ...........................................................................................58 1 Solutions .......................................................................................................................58 1.1 Phosphate-buffered saline .....................................................................................58 1.2 Tris-HCl (1 M) ......................................................................................................58 1.3 Tris-buffered saline (TBS) ....................................................................................58 1.4 10X SDS-PAGE running buffer ............................................................................59 1.5 10X transfer buffer ................................................................................................59 1.6 50X TAE (Tris-Acetate-EDTA) ............................................................................59 2 Protein buffers ..............................................................................................................59 3 2.1 1X JS buffer .......................................................................................................... 59 2.2 1X RIPA buffer ..................................................................................................... 60 2.3 1X Laemmli buffer................................................................................................ 60 3 Reagents ....................................................................................................................... 61 3.1 Antibodies ............................................................................................................. 61 3.2 RNAi oligos .......................................................................................................... 62 3.2.1 Negative control siRNA ................................................................................ 62 3.2.2 Specific RNAi oligos ..................................................................................... 62 3.3 TaqMAN assays for qRT-PCR (Applied Biosystems) ......................................... 62 4 Cloning techniques ...................................................................................................... 63 4.1 Agarose gel electrophoresis .................................................................................. 63 4.2 Minipreps .............................................................................................................. 63 4.3 Diagnostic DNA restriction .................................................................................. 63 4.4 Large scale plasmid preparation ........................................................................... 63 4.5 Transformation of competent cells ....................................................................... 64 5 Constructs and plasmids .............................................................................................. 64 6 Cell culture ................................................................................................................... 65 6.1 Cell culture media ................................................................................................. 65 6.2 Transfections ......................................................................................................... 65 6.2.1 RNAi transfections ........................................................................................ 65 6.2.2 DNA transfections ......................................................................................... 66 6.3 Retroviral and lentiviral infection ......................................................................... 66 4 7 Protein procedures ........................................................................................................67 7.1 Cell lysis ................................................................................................................67 7.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) .......................................67 7.3 Immunoblot (IB) ....................................................................................................68 7.4 Anti-ubiquitin immunoblot ....................................................................................69 7.5 Immmunoprecipitation ..........................................................................................69 8 DUB library screening .................................................................................................70 9 Protein production and purification .............................................................................70 9.1 GST-fusion protein production .............................................................................70 9.2 GST pull-down ......................................................................................................72 10 Assays with 125I-EGF and 125I-Tf .................................................................................72 10.1 Receptor internalization assays with 125I-EGF and 125I-Tf ................................72 10.2 Measurement of the number of EGF/Tf receptors at the cell surface by saturation binding
Recommended publications
  • Chr21 Protein-Protein Interactions: Enrichment in Products Involved in Intellectual Disabilities, Autism and Late Onset Alzheimer Disease
    bioRxiv preprint doi: https://doi.org/10.1101/2019.12.11.872606; this version posted December 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Chr21 protein-protein interactions: enrichment in products involved in intellectual disabilities, autism and Late Onset Alzheimer Disease Julia Viard1,2*, Yann Loe-Mie1*, Rachel Daudin1, Malik Khelfaoui1, Christine Plancon2, Anne Boland2, Francisco Tejedor3, Richard L. Huganir4, Eunjoon Kim5, Makoto Kinoshita6, Guofa Liu7, Volker Haucke8, Thomas Moncion9, Eugene Yu10, Valérie Hindie9, Henri Bléhaut11, Clotilde Mircher12, Yann Herault13,14,15,16,17, Jean-François Deleuze2, Jean- Christophe Rain9, Michel Simonneau1, 18, 19, 20** and Aude-Marie Lepagnol- Bestel1** 1 Centre Psychiatrie & Neurosciences, INSERM U894, 75014 Paris, France 2 Laboratoire de génomique fonctionnelle, CNG, CEA, Evry 3 Instituto de Neurociencias CSIC-UMH, Universidad Miguel Hernandez-Campus de San Juan 03550 San Juan (Alicante), Spain 4 Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 USA 5 Center for Synaptic Brain Dysfunctions, Institute for Basic Science, Daejeon 34141, Republic of Korea 6 Department of Molecular Biology, Division of Biological Science, Nagoya University Graduate School of Science, Furo, Chikusa, Nagoya, Japan 7 Department of Biological Sciences, University of Toledo, Toledo, OH, 43606, USA 8 Leibniz Forschungsinstitut für Molekulare Pharmakologie
    [Show full text]
  • Role of Ubiquitin-Specific Protease 25 in The
    ROLE OF UBIQUITIN-SPECIFIC PROTEASE 25 IN THE PATHOGENESIS OF ALZHEIMER’S DISEASE IN DOWN SYNDROME by Beibei Song B.Sc., Memorial University, 2013 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENT FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE AND POSTDOCTORAL STUDIES (Neuroscience) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) August 2018 © Beibei Song, 2018 The following individuals certify that they have read, and recommend to the Faculty of Graduate and Postdoctoral Studies for acceptance, the dissertation entitled: Role of USP25 in the Pathogenesis of Alzheimer’s Disease in Down Syndrome submitted by Beibei Song in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Neuroscience Examining Committee: Weihong Song Supervisor Yutian Wang Supervisory Committee Member Xin-Ming, Li External Examiner Honglin Luo University Examiner Christian Kastrup University Examiner Additional Supervisory Committee Members: Ann Marie Craig Supervisory Committee Member Jason Snyder Supervisory Committee Member ii Abstract Down syndrome (DS) is the most common genetic cause of intellectual disabilities. Trisomy 21, an extra copy of human chromosome 21, causes the majority of DS cases. After middle age, individuals with DS inevitably develop Alzheimer’s disease, the most common form of neurodegenerative diseases characterized by extracellular amyloid plaque deposition, intracellular neuritic fibrillary tangles and neuronal loss. The extracellular amyloid plaques are made of amyloid β (Aβ) proteins derived from β- and γ- cleavage of amyloid precursor protein (APP). The abnormal accumulation of Aβ proteins plays an essential role in AD pathogenesis. Ubiquitin-specific protease 25 (USP25) is a deubiquitinating enzyme that locates in the DS critical region of human chromosome 21.
    [Show full text]
  • Ubiquitin-Dependent Regulation of the WNT Cargo Protein EVI/WLS Handelt Es Sich Um Meine Eigenständig Erbrachte Leistung
    DISSERTATION submitted to the Combined Faculty of Natural Sciences and Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the degree of Doctor of Natural Sciences presented by Lucie Magdalena Wolf, M.Sc. born in Nuremberg, Germany Date of oral examination: 2nd February 2021 Ubiquitin-dependent regulation of the WNT cargo protein EVI/WLS Referees: Prof. Dr. Michael Boutros apl. Prof. Dr. Viktor Umansky If you don’t think you might, you won’t. Terry Pratchett This work was accomplished from August 2015 to November 2020 under the supervision of Prof. Dr. Michael Boutros in the Division of Signalling and Functional Genomics at the German Cancer Research Center (DKFZ), Heidelberg, Germany. Contents Contents ......................................................................................................................... ix 1 Abstract ....................................................................................................................xiii 1 Zusammenfassung .................................................................................................... xv 2 Introduction ................................................................................................................ 1 2.1 The WNT signalling pathways and cancer ........................................................................ 1 2.1.1 Intercellular communication ........................................................................................ 1 2.1.2 WNT ligands are conserved morphogens .................................................................
    [Show full text]
  • USP25 Antibody (Pab)
    21.10.2014USP25 antibody (pAb) Rabbit Anti -Human/M ouse Ubiquitin specific peptidase 25 (USP21) Instruction Manual Catalog Number PK-AB718-7765 Synonyms Ubiquitin specific peptidase 25, deubiquitinating enzyme 25, ubiquitin carboxyl-terminal hydrolase 25, ubiquitin thiolesterase 25, USP21, USP on chromosome 21 Description USP25 (ubiquitin specific peptidase 25), also known as USP21, belongs to the peptidase C19 family and is a highly conserved 76-amino acid protein involved in regulation of intracellular protein breakdown, cell cycle regulation, and stress response (1). It contains one UBA-like domain and two UIM (ubiquitin-interacting motif) repeats. Due to alternative splicing events, USP25 is expressed as two short, ubiquitously expressed isoforms and one long, muscle-specific isoform (2). The long isoform of USP25 (USP25m) is upregulated in myogenesis and is implicated in regulation of muscular differentiation and function. USP25 is a deubiquitinating enzyme (DUB) that negatively regulates IL-17-triggered signaling (3,4). Quantity 100 µg Source / Host Rabbit Immunogen USP25 antibody was raised against a 17 amino acid peptide near the center of human USP25. Purification Method Affinity chromatography purified via peptide column. Clone / IgG Subtype Polyclonal antibody Species Reactivity Human, Mouse Specificity USP25 antibody is human and mouse reactive. Multiple isoforms of USP25 are known to exist. Formulation Antibody is supplied in PBS containing 0.02% sodium azide. Reconstitution During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 μl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap.
    [Show full text]
  • Ohnologs in the Human Genome Are Dosage Balanced and Frequently Associated with Disease
    Ohnologs in the human genome are dosage balanced and frequently associated with disease Takashi Makino1 and Aoife McLysaght2 Smurfit Institute of Genetics, University of Dublin, Trinity College, Dublin 2, Ireland Edited by Michael Freeling, University of California, Berkeley, CA, and approved April 9, 2010 (received for review December 21, 2009) About 30% of protein-coding genes in the human genome are been duplicated by WGD, subsequent loss of individual genes related through two whole genome duplication (WGD) events. would result in a dosage imbalance due to insufficient gene Although WGD is often credited with great evolutionary impor- product, thus leading to biased retention of dosage-balanced tance, the processes governing the retention of these genes and ohnologs. In fact, evidence for preferential retention of dosage- their biological significance remain unclear. One increasingly pop- balanced genes after WGD is accumulating (4, 7, 11–20). Copy ular hypothesis is that dosage balance constraints are a major number variation [copy number polymorphism (CNV)] describes determinant of duplicate gene retention. We test this hypothesis population level polymorphism of small segmental duplications and show that WGD-duplicated genes (ohnologs) have rarely and is known to directly correlate with gene expression levels (21– experienced subsequent small-scale duplication (SSD) and are also 24). Thus, CNV of dosage-balanced genes is also expected to be refractory to copy number variation (CNV) in human populations deleterious. This model predicts that retained ohnologs should be and are thus likely to be sensitive to relative quantities (i.e., they are enriched for dosage-balanced genes that are resistant to sub- dosage-balanced).
    [Show full text]
  • Product Data Sheet
    For research purposes only, not for human use Product Data Sheet Anti-USP25 Antibody Catalog # Source Reactivity Applications CQA1706 Rabbit H, M, R WB, IH Description Rabbit polyclonal antibody to USP25 Immunogen Recombinant full length protein of human USP25 Purification The antibody was purified by immunogen affinity chromatography. Specificity Recognizes endogenous levels of USP25 protein. Clonality Polyclonal Conjugation Form Liquid in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide. Dilution WB (1/500 - 1/2 000), IH (1/50 - 1/200) Gene Symbol USP25 Alternative Names USP21; Ubiquitin carboxyl-terminal hydrolase 25; Deubiquitinating enzyme 25; USP on chromosome 21; Ubiquitin thioesterase 25; Ubiquitin-specific-processing protease 25 Entrez Gene 29761 (Human); 30940 (Mouse) SwissProt Q9UHP3 (Human); P57080 (Mouse) Storage/Stability Shipped at 4°C. Upon delivery aliquot and store at -20°C for one year. Avoid freeze/thaw cycles. Application key: E- ELISA, WB- Western blot, IH- Immunohistochemistry, IF- Immunofluorescence, FC- Flow cytometry, IC- Immunocytochemistry, IP- Immunoprecipitation, ChIP- Chromatin Immunoprecipitation, EMSA- Electrophoretic Mobility Shift Assay, BL- Blocking, SE- Sandwich ELISA, CBE- Cell-based ELISA, RNAi- RNA interference Species reactivity key: H- Human, M- Mouse, R- Rat, B- Bovine, C- Chicken, D- Dog, G- Goat, Mk- Monkey, P- Pig, Rb- Rabbit, S- Sheep, Z- Zebrafish COHESION BIOSCIENCES LIMITED WEB ORDER SUPPORT CUSTOM www.cohesionbio.com [email protected] [email protected] [email protected] For research purposes only, not for human use Product Data Sheet Western blot analysis of USP25 expression in SKOV3 (A), PC12 (B), mouse brain (C), mouse liver (D) whole cell lysates.
    [Show full text]
  • The Role of Deubiquitinating Enzymes in Acute Lung Injury and Acute Respiratory Distress Syndrome
    International Journal of Molecular Sciences Review The Role of Deubiquitinating Enzymes in Acute Lung Injury and Acute Respiratory Distress Syndrome Tiao Li and Chunbin Zou * Division of Pulmonary, Allergy, Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; [email protected] * Correspondence: [email protected]; Tel.: +(412)-624-3666 Received: 1 June 2020; Accepted: 5 July 2020; Published: 8 July 2020 Abstract: Acute lung injury and acute respiratory distress syndrome (ALI/ARDS) are characterized by an inflammatory response, alveolar edema, and hypoxemia. ARDS occurs most often in the settings of pneumonia, sepsis, aspiration of gastric contents, or severe trauma. The prevalence of ARDS is approximately 10% in patients of intensive care. There is no effective remedy with mortality high at 30–40%. Most functional proteins are dynamic and stringently governed by ubiquitin proteasomal degradation. Protein ubiquitination is reversible, the covalently attached monoubiquitin or polyubiquitin moieties within the targeted protein can be removed by a group of enzymes called deubiquitinating enzymes (DUBs). Deubiquitination plays an important role in the pathobiology of ALI/ARDS as it regulates proteins critical in engagement of the alveolo-capillary barrier and in the inflammatory response. In this review, we provide an overview of how DUBs emerge in pathogen-induced pulmonary inflammation and related aspects in ALI/ARDS. Better understanding of deubiquitination-relatedsignaling may lead to novel therapeutic approaches by targeting specific elements of the deubiquitination pathways. Keywords: acute lung injury/acute respiratory distress syndrome; deubiquitinating enzyme; protein stability; inflammation; infection 1. Introduction Acute lung injury and acute respiratory distress syndrome (ALI/ARDS) are a group of illnesses with features of lung inflammation, air–blood barrier disfunction, and hypoxemia.
    [Show full text]
  • An Epigenome-Wide Association Study Based on Cell Type
    Integrative Molecular Medicine Research Article ISSN: 2056-6360 An epigenome-wide association study based on cell type- specific whole-genome bisulfite sequencing: Screening for DNA methylation signatures associated with bone mass Shohei Komaki1, Hideki Ohmomo1,2, Tsuyoshi Hachiya1, Ryohei Furukawa1, Yuh Shiwa1,2, Mamoru Satoh1,2, Ryujin Endo3,4, Minoru Doita5, Makoto Sasaki6,7 and Atsushi Shimizu1 1Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba, Shiwa, Iwate 028-3694, Japan 2Division of Biobank and Data Management, Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba, Shiwa, Iwate 028-3694, Japan 3Division of Public Relations and Planning, Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba, Shiwa, Iwate 028-3694, Japan 4Division of Medical Fundamentals for Nursing, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba, Shiwa, Iwate 028-3694, Japan 5Department of Orthopaedic Surgery, School of Medicine, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan 6Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba, Shiwa, Iwate 028-3694, Japan 7Division of Ultrahigh Field MRI, Institute for Biomedical Sciences, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba, Shiwa, Iwate 028-3694, Japan Abstract Bone mass can change intra-individually due to aging or environmental factors. Understanding the regulation of bone metabolism by epigenetic factors, such as DNA methylation, is essential to further our understanding of bone biology and facilitate the prevention of osteoporosis. To date, a single epigenome-wide association study (EWAS) of bone density has been reported, and our knowledge of epigenetic mechanisms in bone biology is strictly limited.
    [Show full text]
  • Mammalian Meiotic Silencing Exhibits Sexually Dimorphic Features
    Chromosoma (2016) 125:215–226 DOI 10.1007/s00412-015-0568-z ORIGINAL ARTICLE Mammalian meiotic silencing exhibits sexually dimorphic features J. M. Cloutier1 & S. K. Mahadevaiah1 & E. ElInati1 & A. Tóth2 & James Turner1 Received: 16 July 2015 /Revised: 24 November 2015 /Accepted: 10 December 2015 /Published online: 28 December 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract During mammalian meiotic prophase I, surveil- of sex-reversed XY female mice reveals that the sexual dimor- lance mechanisms exist to ensure that germ cells with defec- phism in silencing is determined by gonadal sex rather than tive synapsis or recombination are eliminated, thereby sex chromosome constitution. We propose that sex differences preventing the generation of aneuploid gametes and embryos. in meiotic silencing impact on the sexually dimorphic pro- Meiosis in females is more error-prone than in males, and this phase I response to asynapsis. is in part because the prophase I surveillance mechanisms are less efficient in females. A mechanistic understanding of this Keywords Meiosis . Meiotic silencing . Oocytes . sexual dimorphism is currently lacking. In both sexes, Epigenetics . Checkpoints . Sex differences asynapsed chromosomes are transcriptionally inactivated by ATR-dependent phosphorylation of histone H2AFX. This process, termed meiotic silencing, has been proposed to per- Introduction form an important prophase I surveillance role. While the transcriptional effects of meiotic silencing at individual genes Meiosis is a dual cell division that halves the chromosome are well described in the male germ line, analogous studies in content of diploid germ cells. Defects in meiosis can result the female germ line have not been performed.
    [Show full text]
  • Downloaded from the Mouse Lysosome Gene Database, Mlgdb
    1 Supplemental Figure Legends 2 3 Supplemental Figure S1: Epidermal-specific mTORC1 gain-of-function models show 4 increased mTORC1 activation and down-regulate EGFR and HER2 protein expression in a 5 mTORC1-sensitive manner. (A) Immunoblotting of Rheb1 S16H flox/flox keratinocyte cultures 6 infected with empty or adenoviral cre recombinase for markers of mTORC1 (p-S6, p-4E-BP1) 7 activity. (B) Tsc1 cKO epidermal lysates also show decreased expression of TSC2 by 8 immunoblotting of the same experiment as in Figure 2A. (C) Immunoblotting of Tsc2 flox/flox 9 keratinocyte cultures infected with empty or adenoviral cre recombinase showing decreased EGFR 10 and HER2 protein expression. (D) Expression of EGFR and HER2 was decreased in Tsc1 cre 11 keratinocytes compared to empty controls, and up-regulated in response to Torin1 (1µM, 24 hrs), 12 by immunoblot analyses. Immunoblots are contemporaneous and parallel from the same biological 13 replicate and represent the same experiment as depicted in Figure 7B. (E) Densitometry 14 quantification of representative immunoblot experiments shown in Figures 2E and S1D (r≥3; error 15 bars represent STDEV; p-values by Student’s T-test). 16 17 18 19 20 21 22 23 Supplemental Figure S2: EGFR and HER2 transcription are unchanged with epidermal/ 24 keratinocyte Tsc1 or Rptor loss. Egfr and Her2 mRNA levels in (A) Tsc1 cKO epidermal lysates, 25 (B) Tsc1 cKO keratinocyte lysates and(C) Tsc1 cre keratinocyte lysates are minimally altered 26 compared to their respective controls. (r≥3; error bars represent STDEV; p-values by Student’s T- 27 test).
    [Show full text]
  • The DNA Sequence of Human Chromosome 21
    articles The DNA sequence of human chromosome 21 The chromosome 21 mapping and sequencing consortium M. Hattori*, A. Fujiyama*, T. D. Taylor*, H. Watanabe*, T. Yada*, H.-S. Park*, A. Toyoda*, K. Ishii*, Y. Totoki*, D.-K. Choi*, E. Soeda², M. Ohki³, T. Takagi§, Y. Sakaki*§; S. Taudienk, K. Blechschmidtk, A. Polleyk, U. Menzelk, J. Delabar¶, K. Kumpfk, R. Lehmannk, D. Patterson#, K. Reichwaldk, A. Rumpk, M. Schillhabelk, A. Schudyk, W. Zimmermannk, A. Rosenthalk; J. KudohI, K. ShibuyaI, K. KawasakiI, S. AsakawaI, A. ShintaniI, T. SasakiI, K. NagamineI, S. MitsuyamaI, S. E. Antonarakis**, S. MinoshimaI, N. ShimizuI, G. Nordsiek²², K. Hornischer²², P. Brandt²², M. Scharfe²², O. SchoÈn²², A. Desario³³, J. Reichelt²², G. Kauer²²,H.BloÈcker²²; J. Ramser§§, A. Beck§§, S. Klages§§, S. Hennig§§, L. Riesselmann§§, E. Dagand§§, T. Haaf§§, S. Wehrmeyer§§, K. Borzym§§, K. Gardiner#, D. Nizetickk, F. Francis§§, H. Lehrach§§, R. Reinhardt§§ & M.-L. Yaspo§§ Consortium Institutions: * RIKEN, Genomic Sciences Center, Sagamihara 228-8555, Japan k Institut fuÈr Molekulare Biotechnologie, Genomanalyse, D-07745 Jena, Germany I Department of Molecular Biology, Keio University School of Medicine, Tokyo 160-8582, Japan ²² GBF (German Research Centre for Biotechnology), Genome Analysis, D-38124 Braunschweig, Germany §§ Max-Planck-Institut fuÈr Molekulare Genetik, D-14195 Berlin-Dahlem, Germany Collaborating Institutions: ² RIKEN, Life Science Tsukuba Research Center, Tsukuba 305-0074, Japan ³ Cancer Genomics Division, National Cancer Center Research Institute,
    [Show full text]
  • Anti-USP25 Antibody (ARG54950)
    Product datasheet [email protected] ARG54950 Package: 50 μg anti-USP25 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes USP25 Tested Reactivity Hu, Ms Tested Application ELISA, ICC/IF, IHC-P, WB Specificity USP25 antibody is human and mouse reactive. Multiple isoforms of USP25 are known to exist. Host Rabbit Clonality Polyclonal Isotype IgG Target Name USP25 Antigen Species Human Immunogen Synthetic peptide (17 aa) within aa. 470-520 of Human USP25. Conjugation Un-conjugated Alternate Names USP on chromosome 21; Ubiquitin-specific-processing protease 25; Ubiquitin carboxyl-terminal hydrolase 25; Deubiquitinating enzyme 25; Ubiquitin thioesterase 25; USP21; EC 3.4.19.12 Application Instructions Application table Application Dilution ELISA Assay-dependent ICC/IF 20 μg/ml IHC-P 5 μg/ml WB 1 - 2 μg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse Brain Tissue Lysate Calculated Mw 122 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer PBS and 0.02% Sodium azide Preservative 0.02% Sodium azide Concentration 1 mg/ml www.arigobio.com 1/3 Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use.
    [Show full text]